HB 1741 Pennsylvania House · 2021-2022 Regular Session

An Act providing for prescribing and dispensing drugs approved by the United States Food and Drug Administration for off-label use to treat coronavirus infections causing respiratory syndrome-related illnesses.

Bill status in committee 3 of 5 stages cleared
Introduction
Jul 2021
Committee Review
Jun 2022
House Passage
Jun 2022
Senate Passage
Governor
Introduced Jul 30, 2021 Last action Jun 14, 2022
Floor votes · House Jun 14, 2022

How they voted

10684
Passed · 2 other
Total votes 192
Jun 14, 2022
D Democratic84
83 Nay 1
98% Nay
R Republican108
106 Yea 1 Nay 1
98% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
10
Key actions
2
Committee
2
Amendments
1
Jun 14, 2022
House · Passed
House Vote: pass (106-84-2)
house
Jun 14, 2022
Committee
Re-committed to APPROPRIATIONS
lower
Feb 7, 2022
Lower · Passed
PN 2713 Reported as amended
lower
Jul 30, 2021
Committee
PN 1972 Referred to HEALTH
lower
1 primary · 17 co-sponsors

Sponsors